key: cord-0956386-yo0c42rg
authors: Israr, Muhammad Zubair; Ibrahim, Wadah; Salzano, Andrea; Sarmad, Sarir; Wilde, Michael J.; Cordell, Rebecca L.; Greening, Neil J.; Brightling, Christopher E.; Siddiqui, Salman; Suzuki, Toru
title: Gut-related metabolites are associated with respiratory symptoms in COVID-19: a proof-of-concept study
date: 2022-01-05
journal: Nutrition
DOI: 10.1016/j.nut.2021.111585
sha: b13e95d22bbd1fed416dcc37c028c49f61237c05
doc_id: 956386
cord_uid: yo0c42rg

Gut-related metabolites have been linked with respiratory disease. The crosstalk between the gut and lung suggests that gut health may be compromised in COVID-19. The aims of the present study were to analyse a panel of gut-related metabolites (acetyl-L-carnitine, betaine, choline, L-carnitine, trimethylamine and TMAO) in COVID-19 patients, matched with healthy subjects, and non-COVID-19 respiratory patients. As results, metabolites from this panel are impaired in COVID-19, associated with symptoms (breathlessness and temperature) and able to differentiate between COVID-19 and asthma. Preliminary results show lower levels of betaine appear to be associated with poor outcomes in COVID-19 patients suggesting betaine as a marker of gut microbiome health.

Increasing evidence suggests the gut may be compromised by COVID-19 [1, 2] . The gut microbiome is essential to health and wellbeing, whilst gut microbiota perturbations are linked with many diseases, included respiratory [3] . Despite the anatomic distinctions between the gut and lungs, recent evidence into the lung microbiota has identified crosstalk with the gut microbiota [4] . One mechanism of gut-lung crosstalk is by the distribution of gut metabolites. A gut-derived metabolite, trimethylamine N-oxide (TMAO) has been identified as a novel marker of gut health and disease in particular in cardiometabolic diseases, showing associations with disease severity and outcome, diet, ethnicity, gender and lifestyle; and would therefore be suitable to investigate the associations of the gut in COVID-19 [5] . The aims of the present study were to investigate the association of circulating levels of gutrelated metabolites (acetyl-L-carnitine, betaine, choline, L-carnitine, trimethylamine and TMAO) in COVID-19 patients. We hypothesise that COVID-19 patients will have different levels of metabolites compared to healthy individuals due to compromised gut health.

Furthermore, we compared COVID-19 with patients affected by other acute respiratory diseases (i.e., acute asthma, pneumonia).

Patients with acute COVID-19 (n=41) were recruited on admission at Glenfield General Hospital, Leicester (UK) and matched by age and gender with plasma samples from healthy (n=28), acute asthma (n=30), and pneumonia (n=24) patients. Each patient consented to have blood samples taken and outcomes surveyed. Gut-related metabolites were measured using liquid chromatography-tandem mass spectrometry [6] .

Statistical analyses were performed using IBM SPSS Statistics (V26, IBM Corp., Armonk, New York, USA). Association and distribution of metabolites between the groups and with clinical features were analysed using Spearman's rank correlation and Kruskal-Wallis test. Comparisons between COVID and non-COVID groups were performed using Mann-Whitney test for continuous variables and chi-square test for categorical. A one-way ANOVA was used to compare metabolite levels across each of the study groups. A p-value <0.05 was considered statistically significant.

Study demographics showed that the COVID-19 cohort were majority male (68%) with a median age of 54 years. The majority of patients reported breathlessness (90%) and a new or continuous cough (76%) ( Table 1 ). Distribution of metabolites showed no significant difference between COVID-19 and healthy patients for acetyl-L-carnitine, choline, Lcarnitine, trimethylamine and TMAO (p≥0.056); however, there was a difference in betaine levels between these groups (p=0.010), with higher levels in the healthy cohort, but not after Bonferroni correction (adj. p=0.058). No differences between COVID-19 and pneumonia were observed (p≥0.059, adj. p≥0.352). Furthermore, patients with asthma demonstrated lower levels of acetyl-L-carnitine, betaine, and choline, and higher levels of trimethylamine when compared with COVID-19 patients (adj. p<0.001) (Table 2A) . Similar patterns were observed when asthma and healthy patients were compared (adj. p≤0.030). There was an overall significant difference in metabolite distribution between the study groups (p≤0.028), with a notable difference in distribution of acetyl-L-carnitine, betaine, choline, L-carnitine and TMA, between COVID-19 and asthma (p≤0.020) ( Figure 1 ). Distribution of metabolites with COVID-19 symptoms (breathlessness, fatigue, loss of smell and/or taste, new, continuous cough and runny nose) were analysed and showed elevated levels of acetyl-Lcarnitine and L-carnitine in patients who reported with breathlessness. There were no other significant observations (Table 2B) . Additionally, betaine and TMAO showed negative correlations with temperature (r s = -0.395 and -0.344 respectively, p≤0.028), whilst betaine also correlated with O 2 saturation levels (r s = 0.312, p=0.050) (Table 2C ). Comorbidities were grouped into three groups; diabetes, cardiac disease and chronic pulmonary disease. We found no significant differences in metabolite levels for patients who reported to have chronic pulmonary disease (n=10, p≥0.191) and also for diabetes (n=9, p≥0.295). However, in patients who had cardiac disease (n=6), we found elevated levels of betaine, choline, Lcarnitine, and TMAO (p≤0.049). Furthermore, there was no significant difference in metabolite levels when at least one comorbidity (i.e., diabetes + cardiac disease + chronic pulmonary disease) was present (p≥0.101). Kaplan-Meier survival analysis showed that when betaine levels were split by the median, a trend was observed between lower betaine levels and reduced survival (greater than 2-fold lower than those with higher betaine levels) (p=0.407).

To the best of our knowledge, this is the first study investigating associations of gutrelated metabolites with COVID-19. The main finding from the present study is that metabolites from the choline/carnitine-TMAO pathway are associated with COVID-19 symptoms (breathlessness and temperature) and severity (O 2 saturation levels), and were able to differentiate between COVID-19 and acute asthma.

Growing evidence indicates a key crosstalk that allows maintaining homeostasis and disease evolution. The gut-lung axis concept however, is not completely understood despite recent evidence identifying host-microbe as well as microbe-microbe interactions [7] .

Patients with respiratory infections typically have gut dysfunction or secondary gut dysfunction complications, suggesting a gut-lung interaction [3] . Gut microbiota influence on lung microbial composition and disease has been proposed by two crosstalk mechanisms i) direct seeding of the respiratory tract with bacteria and ii) the distribution of bacterial metabolites [8] . Increasing evidence supports a "common mucosal response" where the effects of the gut microbiota on the mucosal immunity may influence an immune response on distal mucosal sites including the lung, whilst gut bacterial cells and metabolites may also elicit immune response at distal sites [9] . An alternative mechanism of the gut-lung interaction is by systemic dissemination of metabolites. Current research has investigated the role of short chain fatty acids (SCFA) which can suppress lung inflammation through the activation of G protein-coupled receptors and exert anti-inflammatory properties [10].

In all, we investigated whether the distribution of metabolites was associated with COVID-19. We focused on the choline and carnitine pathways, which are derived from dietary sources of red meat, fish and eggs, and converge into a common metabolite, TMAO.

TMAO is formed from the bacterial cleavage of trimethylamine [6] . Limitations of the study include the proof-of-concept design, with a small sample size coupled with low numbers of mortality that could influence the results. As consideration, these metabolites are related to the gut microbiota, it is therefore necessary to take into account dietary data, treatment (i.e., antibiotics), and whether the patients take supplements or not, since the detected levels could come not only from the metabolism of the intestinal microbes but also directly from these sources.

In conclusion, we showed for the first time that gut-related metabolites, in particular betaine, are associated with COVID-19 symptoms. Lower levels of metabolites in asthma and COVID-19, in particular betaine, suggests a role for betaine as a surrogate marker for gut health in COVID-19, and hypothesises that dietary intervention against the gut microbiome could improve outcomes, and enhance immunity. Validation studies are warranted. Whiskers show 10-90% percentile. Statistical significance between the COVID-19 cohort and healthy, asthma and pneumonia groups are also displayed. 

The trinity of COVID-19: immunity, inflammation and intervention

novel coronavirus infection and gastrointestinal tract

The gut microbiota and respiratory diseases: new evidence

Emerging pathogenic links between microbiota and the gut-lung axis

The Gut Axis Involvement in Heart Failure: Focus on Trimethylamine N-oxide

Association of gut-related metabolites with outcome in acute heart failure

The gut-lung axis in health and respiratory diseases: a place for inter-organ and inter-kingdom crosstalks

The gut-lung axis in respiratory disease

The possible mechanisms of the human microbiome in allergic diseases

The authors report no disclosures.

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.